New drug candidate B-OT takes first step in human safety trial

NCT ID NCT07450833

Completed Knowledge-focused Sponsor: Benfovir AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety and tolerability of an experimental drug called Benfo-Oxythiamine (B-OT) in 48 healthy male volunteers. Researchers gave the drug as single or multiple daily doses and monitored participants closely for side effects, blood levels, and lab changes. The goal was to see if B-OT is safe enough to study further for possible use against infectious diseases and cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Benfo-oxythiamine (B-OT)
What this could lead to: If this drug proves safe, it could pave the way for future studies testing B-OT as a treatment for infectious diseases or cancer.
What could go wrong: This is a very early Phase 1 trial in only 48 healthy volunteers. It only looks at safety and how the drug moves through the body, not whether it works against any disease. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 Korsakoff Syndrome neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Diagnostics and Consultation Center (DCC) Convex EOOD

Sofia, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.